Addex Therapeutics Ltd - American Depositary Shares (ADXN)
ADXN moved a median of -0.23% 30 minutes after news, and -1.02% by the close. How ADXN actually reacts to news — the realized, point-in-time move the market made, measured across 219 labeled events over the last three years with zero look-ahead.
ADXN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 23% | 104 |
| 30-min | -0.23% | 34% | 155 |
| 60-min | -0.50% | 35% | 162 |
| to close | -1.02% | 35% | 217 |
| Middle 50% of ADXN reactions | -3.43% to +0.34% |
|---|---|
| Median reaction (30-min) | -0.23% |
| Measured reactions | 219 |
Half of all Addex Therapeutics Ltd - American Depositary Shares news events land between -3.43% and +0.34% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ADXN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ADXN's baseline. Nothing else.
Recent ADXN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Addex Therapeutics Ltd. For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.24% | |
| Addex Therapeutics Announces Executive Management Changes | Press release | GlobeNewswire | — | +2.68% | |
| Form 6-K Addex Therapeutics Ltd. For: Oct 02 | SEC filing · Form 6-K | SEC EDGAR | — | +2.68% | |
| Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update | Press release | GlobeNewswire | -3.74% | -24.87% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.74% | -24.87% | |
| Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior | Press release | GlobeNewswire | +0.00% | +0.83% | |
| Form 6-K Addex Therapeutics Ltd. For: Sep 25 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.83% | |
| Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 | Press release | GlobeNewswire | — | -0.29% | |
| ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027 | Press release | GlobeNewswire | -1.24% | -4.51% | |
| Form 6-K Addex Therapeutics Ltd. For: Aug 26 | SEC filing · Form 6-K | SEC EDGAR | -1.24% | -4.51% | |
| Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness | Press release | GlobeNewswire | — | -3.28% | |
| Form 6-K Addex Therapeutics Ltd. For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | — | -3.28% | |
| Addex Shareholders Approve All Resolutions at Annual General Meeting | Press release | GlobeNewswire | — | -2.56% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | — | -2.56% | |
| Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.17% | -1.98% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | -0.17% | -1.98% | |
| Addex Convenes Annual General Meeting 2026 | Press release | GlobeNewswire | — | -9.98% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | — | -9.98% | |
| Form 20-F Addex Therapeutics Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | +3.96% | |
| Addex Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -0.57% | |
| Form 6-K Addex Therapeutics Ltd. For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | — | -0.57% | |
| Form NT 20-F Addex Therapeutics Ltd. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -0.86% | +0.57% | |
| Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model | Press release | GlobeNewswire | — | +1.30% | |
| Form 6-K Addex Therapeutics Ltd. For: Apr 29 | SEC filing · Form 6-K | SEC EDGAR | — | +1.30% | |
| Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 | Press release | GlobeNewswire | — | -6.83% | |
| Form 6-K Addex Therapeutics Ltd. For: Apr 23 | SEC filing · Form 6-K | SEC EDGAR | — | -6.83% | |
| Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model | Press release | GlobeNewswire | +0.00% | -0.14% | |
| Form 6-K Addex Therapeutics Ltd. For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.14% | |
| Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment | Press release | GlobeNewswire | — | -3.63% | |
| Form 6-K Addex Therapeutics Ltd. For: Feb 03 | SEC filing · Form 6-K | SEC EDGAR | — | -3.63% | |
| Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia | Press release | GlobeNewswire | — | -3.41% | |
| Form 6-K Addex Therapeutics Ltd. For: Jan 07 | SEC filing · Form 6-K | SEC EDGAR | — | -3.41% | |
| Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. | Press release | GlobeNewswire | — | +3.32% | |
| Form 6-K Addex Therapeutics Ltd. For: Dec 10 | SEC filing · Form 6-K | SEC EDGAR | — | +3.32% | |
| Form EFFECT Addex Therapeutics Ltd. | SEC filing · Form EFFECT | SEC EDGAR | — | +3.87% | |
| Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -4.98% | |
| Form 6-K Addex Therapeutics Ltd. For: Dec 04 | SEC filing · Form 6-K | SEC EDGAR | — | -4.98% | |
| Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 | Press release | GlobeNewswire | -1.43% | +6.49% | |
| Form F-3 Addex Therapeutics Ltd. | SEC filing · Form F-3 | SEC EDGAR | — | -9.51% | |
| Addex Increases Issued Share Capital to Create Treasury Shares | Press release | GlobeNewswire | — | -3.66% | |
| Form 6-K Addex Therapeutics Ltd. For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | — | -3.66% | |
| Form EFFECT Addex Therapeutics Ltd./ | SEC filing · Form EFFECT | SEC EDGAR | — | +2.29% | |
| Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.69% | -5.07% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -1.69% | -5.07% | |
| Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 | Press release | GlobeNewswire | — | -2.98% | |
| Form 6-K Addex Therapeutics Ltd. For: Sep 23 | SEC filing · Form 6-K | SEC EDGAR | — | -6.52% | |
| Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders | Press release | GlobeNewswire | +1.94% | +4.56% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +1.94% | +4.56% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | — | +1.78% | |
| Form 6-K Addex Therapeutics Ltd. For: Jun 20 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -13.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ADXN section they belong to.
Where else ADXN is measured.
ADXN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Addex Therapeutics Ltd - American Depositary Shares's median reaction calculated?
Every labeled ADXN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 219 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of ADXN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ADXN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.